INTRODUCTION {#s1}
============

The urinary bladder is the organ that collects urine excreted from kidneys before disposal by urination. Bladder dysfunction, such as overactive bladder (OAB), has serious effects on quality of life \[[@R1]\]. OAB syndrome is a common condition characterized by the presence of urgency with or without incontinence, frequency, and nocturia. The etiology of OAB syndrome is very complicated and includes increased afferent activity, decreased inhibitory control, and increased sensitivity of the detrusor muscle to efferent stimulation \[[@R2]\]. It has been reported that the overall prevalence of OAB syndrome was 11.8%; rates were similar between men and women \[[@R3]\]. The prevalence of OAB syndrome increased with age in a linear fashion \[[@R3]-[@R5]\]. As a result, in patients over the age of 65 years the prevalence of OAB syndrome can increase to 30.9% \[[@R4]\]. Anticholinergic drugs remain the first-line pharmacologic treatment for OAB syndrome \[[@R6]\] despite producing undesirable side effects such as dry mouth, constipation, and blurred vision \[[@R7]\]. It is estimated that by 2018, more than 500 million people worldwide will be affected by OAB \[[@R3], [@R8]\]. Thus, it is of great urgency to identify novel targets for this disorder.

Bitter taste receptors (TAS2Rs) belong to the superfamily of G-protein-coupled receptors (GPCRs) \[[@R9]\]. GPCRs, which convert extracellular stimuli into intracellular signals through the activation of heterotrimeric G-proteins, are involved in many diseases and are also the target of approximately 40% of all modern medicinal drugs \[[@R10]\]. However, these targeted GPCRs are only a small part of this receptor superfamily and over 30% GPCRs have no known endogenous ligand, indicating that many potential targets remain to be discovered \[[@R11]\]. As TAS2Rs are traditionally thought to be expressed exclusively on the taste buds of the tongue, they have been generally neglected as drug targets. However, accumulating evidence has indicated that this receptor family performs non-gustatory functions outside the mouth in addition to taste. We and others have shown that TAS2Rs are expressed in both human and mouse airway smooth muscle and mediate the tone of airway smooth muscle \[[@R12]-[@R15]\]. Besides, it has been reported that this receptor family plays a critical role in the heart \[[@R16]\], thyroid \[[@R17]\], and gastrointestinal muscle \[[@R18]\]. However, their role in the urinary bladder has never been determined.

In this study, we examined the expression and function of TAS2Rs in human and mouse urinary detrusor smooth muscle (DSM). We further determined their role in the urinary bladder of mice with partial bladder outlet obstruction (PBOO).

RESULTS {#s2}
=======

Expression profile of *Tas2rs* in human DSM {#s2_1}
-------------------------------------------

Using quantitative reverse transcription PCR (RT-qPCR), we screened the expression profile of all 25 *TAS2R* genes in human DSM. As shown in Figure [1](#F1){ref-type="fig"}, we found that *TAS2R7* and *TAS2R8* were the most abundantly expressed genes, with levels similar to the reference gene glyceraldehyde 3-phosphate dehydrogenase (*GAPDH*). The expression levels of *TAS2R1*, *TAS2R5*, *TAS2R9*, *TAS2R13*, *TAS2R20*, and *TAS2R31* were two orders of magnitude lower than that of *GAPDH* with the following rank order: *TAS2R13* \> *TAS2R1*≈*TAS2R9* \> *TAS2R5*≈*TAS2R20*≈*TAS2R31*. *TAS2R4*, *TAS2R10*, *TAS2R14*, *TAS2R30*, *TAS2R38*, *TAS2R39*, *TAS2R40*, *TAS2R45*, and *TAS2R50* were very slightly detected. Eight *TAS2R* genes (*TAS2R3*, *TAS2R16*, *TAS2R19*, *TAS2R41*, *TAS2R42*, *TAS2R43*, *TAS2R46*, and *TAS2R60*) were not expressed.

![The genes of *TAS2R* are expressed in human DSM\
RT-qPCR screen of *TAS2R* genes in human DSM. Data were presented as relative expression of *TAS2R* genes to the reference gene *GAPDH* (mean ± SEM of 5 independent DSM samples). Of all 25 human *TAS2R* gens, 17 *TAS2Rs* were expressed in human DSM with distinct levels, whereas 8 *TAS2R*s were not detected.](oncotarget-07-21156-g001){#F1}

Chloroquine (CLQ) relaxes human DSM strips {#s2_2}
------------------------------------------

Next, we determined the function of TAS2Rs in human DSM with chloroquine (CLQ). CLQ is an agonist of TAS2Rs and has been shown to activate several TAS2Rs, including TAS2R3, TAS2R7, TAS2R10, and TAS2R39 \[[@R19]-[@R21]\]. We showed that CLQ did not exhibit any effects on the base tone of human DSM strips. We thus tested the effect of CLQ on carbachol- and KCl-induced contractions of human DSM strips according to previous studies \[[@R22]-[@R24]\]. We showed that cumulative concentrations of CLQ (100 nM to 3 mM) induced significant decreases of carbachol- and KCl-induced contractions in a concentration-dependent manner (Figure [2A-2D](#F2){ref-type="fig"}). In contrast, the vehicle had no significant effects on these contractions (Figure [2B and 2D](#F2){ref-type="fig"}). Moreover, we investigated the effects of CLQ on the nerve-evoked contractions induced by a wide range of electrical field stimulation (EFS) frequencies as described from Petkov\'s work \[[@R25]\]. We first applied increasing EFS frequencies (0.5-50 Hz) as a control protocol, followed by the addition of 100 μM CLQ (Figure [3E](#F3){ref-type="fig"}). Five minutes after the addition, a second EFS protocol was applied. As shown in Figure [3F](#F3){ref-type="fig"}, CLQ (100 μM) significantly decreased the amplitudes of EFS-induced contractions within a wide range (0.5 Hz, 2 Hz, 3.5 Hz, 5 Hz, 7.5 Hz, 10 Hz, 12.5 Hz, 15 Hz, 20 Hz, 30 Hz, 40 Hz, and 50 Hz) by 21 ± 12%, 52 ± 15%, 26 ± 14%, 32 ± 10%, 31 ± 10%, 40 ± 5%, 50 ± 8%, 55 8%, 46 ± 10%, 48 ± 13%, and 57 ± 19%, respectively. Of all the strips (*n* = 26), only three exhibited spontaneous phasic contractions. We found that CLQ (100 μM) completely inhibited these spontaneous phasic contractions (Figure [2G](#F2){ref-type="fig"}). Taken together, these results suggested that TAS2R activation relaxes human DSM.

![Effect of chloroquine on stimulus-induced and spontaneous contractions of human DSM strips\
**A.**, **B.** Original trace and summary data showing the effects of vehicle (control, *n* = 4 strips) or chloroquine (CLQ: 100 nM to 3 mM; *n* = 5 strips) on carbachol-induced contractions. **C.**, **D.** Original trace and summary data showing the effects of vehicle (control, *n* = 4 strips) or CLQ (100 nM to 3 mM; *n* = 5 strips) on KCl-induced contractions. **E.**, **F.** Original trace and summary data showing the effects of CLQ (100 μM) on EFS-induced contractions (*n*= 4 strips). **G.** Original trace of spontaneous contractions in the absence and presence of 100 μM CLQ. Data are mean ± SEM of n independent DSM strips. \**p* \< 0.05, \*\**p* \< 0.01, and\*\*\**p* \< 0.001 as indicated.](oncotarget-07-21156-g002){#F2}

![The genes of *Tas2r* are expressed in mouse DSM\
RT-qPCR screen of *Tas2r* genes in mouse DSM. Data were presented as relative expression of *Tas2r* genes to the reference gene *Gapdh* (mean ± SEM of 3 independent DSM samples). Of all 35 mouse *Tas2r* genes, 19 *Tas2rs* were expressed in mouse DSM with distinct levels, whereas 16 *Tas2r*s were not detected.](oncotarget-07-21156-g003){#F3}

Expression profile of *Tas2rs* in mouse DSM {#s2_3}
-------------------------------------------

We further explored the expression profile of *Tas2rs* in mouse DSM with RT-qPCR. Of 35 mouse *Tas2r* genes, *Tas2r114*, *Tas2r117*, *Tas2r130*, *Tas2r138*, and *Tas2r144* were significantly expressed. Among them, only *Tas2r114* was expressed at a similar level to *Gapdh*. Fourteen *Tas2r* genes were very lowly expressed, whereas 16 *Tas2r* genes were not detected (Figure [3](#F3){ref-type="fig"}).

Effects of bitter tastants on carbachol-induced contractions in mouse DSM strips {#s2_4}
--------------------------------------------------------------------------------

To determine the role of TAS2Rs in mouse DSM, three different bitter tastants, CLQ, denatonium, and quinine, were used. As shown in Figure [4A-4C](#F4){ref-type="fig"}, we found that CLQ (1 mM) mediated a two-phasic response: it first produced a slight contraction and then completely relaxed the carbachol-induced contractions. Moreover, both denatonium and quinine concentration-dependently decreased carbachol-induced contractions of mouse DSM strips (Figure [4D-4F](#F4){ref-type="fig"}). The vehicle had no significant effects on these contractions (Figure [4F](#F4){ref-type="fig"}).

![Effect of bitter tastants on carbachol-induced contractions of mouse DSM strips\
**A.-C.** Original traces and summary data showing the effects of vehicle (control, *n* = 5 strips) or chloroquine (CLQ: 1 mM; *n* = 6 strips) on carbachol-induced contractions in mouse DSM strips. **D.** Original trace showing the effects of denatonium (100 nM to 3 mM) on carbachol-induced contractions. **E.** Original trace showing the effects of quinine (100 nM to 3 mM) on carbachol-induced contractions. **F.** Summary data showing the effects of vehicle, denatonium (*n* = 5 strips), and quinine (*n* = 5 strips) on carbachol-induced contractions. Data are mean ± SEM of n independent mouse DSM strips. \**p* \< 0.05, \*\**p* \< 0.01, and \*\*\**p* \< 0.001 were control *vs*. CLQ or denatomium; \#*p* \< 0.05, \#\#*p* \< 0.01, and \#\#\#*p* \< 0.001 were control *vs*. quinine, respectively.](oncotarget-07-21156-g004){#F4}

Chloroquine treatment attenuates bladder morphological alteration of PBOO mice {#s2_5}
------------------------------------------------------------------------------

It has been well accepted that detrusor over-activity is one of the major causes of OAB syndrome \[[@R2]\]. Thus, relaxation of the urinary DSM has been recognized as an effective approach to treat OAB. Our *in vitro* results demonstrated that TAS2Rs activation can relax both human and mouse urinary DSM (Figures [2](#F2){ref-type="fig"} and [4](#F4){ref-type="fig"}). We therefore hypothesized that TAS2Rs activation would be effective for the treatment of OAB. To test this hypothesis, we induced a mouse model of OAB through partial obstruction of the urinary bladder outlet. The mean bodyweights of the sham, PBOO-vehicle, and PBOO-CLQ mice were not significantly different (data not shown). As shown in Figure [5A](#F5){ref-type="fig"}, the bladder weights of PBOO-vehicle mice (*N* = 8; 0.031 ± 0.002 g) were significantly increased than that of sham mice (*N* = 8; 0.022 ± 0.002 g); CLQ treatment markedly suppressed this increase (PBOO-CLQ mice: *N* = 8; 0.026 ± 0.001 g). Moreover, hematoxylin-eosin (HE) staining indicated that the bladder muscle thicknesses of PBOO-vehicle mice (*N* = 5; 0.40 ± 0.03 mm) were markedly thicker than that of sham mice (*N* = 5; 0.28 ± 0.02 mm); while CLQ treatment largely prevented PBOO-mediated muscle hypertrophy (PBOO-CLQ mice: *N* = 5; 0.32 ± 0.01 mm) (Figure [5B](#F5){ref-type="fig"}). In all groups, muscle fibers (stained red) and collagen fibers (stained blue) can be clearly observed in the bladder wall (Figure [5C](#F5){ref-type="fig"}). Consistent with HE results, masson\'s trichrome staining also indicated that the bladder walls were thicker in PBOO-vehicle and PBOO-CLQ mice in comparison with sham mice. Additionally, there was a transmural increase in the amount of collagen in both PBOO-vehicle and PBOO-CLQ mice. The collagen/muscle ratio in the muscle layer of bladder wall was significantly increased in PBOO-vehicle mice (*N* = 5; 1.4 ± 0.04) compared to sham mice (*N* = 5; 0.84 ± 0.05); this increase was markedly suppressed by CLQ treatment (PBOO-CLQ mice: *N* = 5; 1.05 ± 0.05).

![Chloroquine treatment significantly attenuates the bladder morphological changes of PBOO mice\
**A.** Bladder weights of the sham (*N* = 8), PBOO-Vehicle (*N* = 8), and PBOO-CLQ (*N* = 8) mice are shown. After anesthesia, the whole bladder was removed and imaged. The fat and connective tissues were cleaned under cold PBS. Then, the bladder was cut from the neck to the fundus along one side. After being quickly dried by drinking paper, the bladder was weighed. **B.** The representative HE stains of bladder specimens from the sham, PBOO-Vehicle, and PBOO-CLQ mice are shown. Summary data showing the average muscle thickness of bladders from the sham (*N* = 5), PBOO-Vehicle (*N* = 5), and PBOO-CLQ (*N* = 5) mice. **C.** The representative Masson\'s trichrome staining of bladder from the sham, PBOO-Vehicle, and PBOO-CLQ mice were shown. Summary data showing the mean ratio of collagen to muscle from the sham (*N* = 5), PBOO-Vehicle (*N* = 5), and PBOO-CLQ (*N* = 5) mice. Scale bars = 250 μm. \**p* \< 0.05 and \*\**p* \< 0.01 as indicated.](oncotarget-07-21156-g005){#F5}

Chloroquine treatment improves bladder function of PBOO mice {#s2_6}
------------------------------------------------------------

We also explored the bladder function of PBOO mice after CLQ treatment. As shown in Figure [6A](#F6){ref-type="fig"}, compared to sham mice, PBOO-Vehicle mice exhibited aberrant urodynamic manifestations; while PBOO-CLQ mice had normal urodynamic features. In detail, maximum micturition pressure of PBOO-Vehicle mice was significantly higher than that of sham mice; CLQ treatment suppressed this increase (Figure [6B](#F6){ref-type="fig"}). PBOO significantly shortened the micturition interval; however, these values were significantly prolonged and increased by CLQ treatment (Figure [6C](#F6){ref-type="fig"}). The micturition frequency of PBOO-Vehicle mice was largely increased compared to sham mice; this value was markedly decreased by CLQ treatment (Figure [6D](#F6){ref-type="fig"}).

![Chloroquine treatment improves the bladder function of PBOO mice\
**A.** The representative traces of the cystometrogram recorded in the sham, PBOO-Vehicle, and PBOO-CLQ mice. **B.-D.** Summary data of micturition pressures, micturition intervals, and voiding frequency of the sham (*N* = 10), PBOO-Vehicle (*N* = 10), and PBOO-CLQ (*N* = 10) mice are shown. Data are mean ± SEM. \**p* \< 0.05, \*\**p* \< 0.01, and \*\*\**p* \< 0.001 as indicated.](oncotarget-07-21156-g006){#F6}

DISCUSSION {#s3}
==========

In this study, we demonstrated for the first time that TAS2Rs exist in human and mouse DSM based on both molecular and pharmacological studies. With RT-qPCR, we determined the expression profile of *TAS2Rs* in human and mouse DSM (Figures [1](#F1){ref-type="fig"} and [3](#F3){ref-type="fig"}). We showed that *TAS2R7* and *TAS2R8* were the main subtypes expressed in human DSM (Figure [1](#F1){ref-type="fig"}). The murine homolog of *TAS2R7*, *Tas2r130*, was significantly detected in mouse DSM (Figure [3](#F3){ref-type="fig"}). Likewise, *Tas2r144* was the major subtype expressed in mouse DSM (Figure [3](#F3){ref-type="fig"}). Its human homolog, *TAS2R40*, was also observed in human DSM (Figure [1](#F1){ref-type="fig"}). However, a large number of *TAS2R* subtypes expressed in human DSM were not detected in mouse DSM. It is perhaps due to the fact that most of them are human specific *TAS2Rs* including *TAS2R5*, *TAS2R8*, *TAS2R9*, *TAS2R30*, *TAS2R31*, and *TAS2R45*. With a classical pharmacological method, we showed that TAS2Rs activation induces a strong relaxation of both human and mouse DSM strips. Of interest, a transient contraction before the relaxation was observed in mouse DSM strips (Figure [4](#F4){ref-type="fig"}). However, this phenomenon did not occurred in human DSM. These results suggested that TAS2Rs and their downstream signaling pathways might be varied among species. Like CLQ, the other two bitter tastants, quinine and denatonium, largely relaxed the carbachol-induced contractions of mouse DSM strips in a concentration dependent manner (Figure [4D-4F](#F4){ref-type="fig"}), confirming the existence of TAS2Rs in mouse DSM. We also found that CLQ had no obvious effects on the base tone but suppressed stimulus-induced contractions of DSM, implying that the underlying signaling pathways might be different between the resting and pre-contracted conditions. It has been shown that TAS2Rs activation mediates two opposing signaling pathways in the airway smooth muscle \[[@R14]\].

In the airway epithelium, TAS2Rs expressed on the ciliated epithelial cells \[[@R26]\] and solitary chemosensory cells \[[@R27], [@R28]\], where they promote ciliary beat frequency and sense chemical irritation, respectively. Here, we did not focus the role of TAS2Rs in the urothelium of urinary bladder. It is hard to obtain the human bladder tissues with normal urothelium in our experimental conditions. In most cases, only the DSM sections were delivered to the lab from the hospital. In order to keep consistent with findings in the human urinary DSM, we only investigated the role of TAS2Rs in mouse DSM. However, it will be very interesting to test the role of TAS2Rs in the urothelium of urinary bladder.

Another primary finding of this study is that CLQ treatment suppresses OAB symptoms. We showed that once daily 30 mg/kg of CLQ for 6 weeks can attenuate PBOO-induced DSM hypertrophy and collagen deposition (Figure [5](#F5){ref-type="fig"}) and improve bladder functions of PBOO mice (Figure [6](#F6){ref-type="fig"}). The dosage of CLQ used in this study was based on previous observations. Sexton et al. showed that 25 and 50 mg/kg of CLQ are effective for the treatment of human malaria \[[@R29]\]. In a murine malaria model, a single dose of 50 mg/kg of CLQ can protect mice from experimental malaria \[[@R30]\]. It has been reported that once daily 30 mg/kg of CLQ has no significant effects on the behavior and appearance of the mice \[[@R31]\]. Moore et al. found that the maximum plasma concentration of CLQ can reach to 1 708 μg/liter (about 6 μM) after the treatment of a single dose of CLQ (50 mg/kg) in the mice \[[@R32]\]. CLQ concentration can be accumulated more than 10 times after the successive treatment of CLQ for 20 days in human \[[@R33]\]. As the pharmacokinetics of CLQ is similar between human and mouse \[[@R32]\], we calculated that the plasma concentration of CLQ should be maintained from 10 to 100 μM during CLQ treatment. After PBOO surgery, the bladder underwent structural and functional remodeling to adapt the excessive mechanical stress \[[@R34]\]. One of the major functional alterations caused by PBOO is detrusor over-activity, which is characterized by increased responses to stimuli and micturition dysfunction. The super-sensitivity of the detrusor to acetylcholine (Ach) has been reported in the animal model \[[@R35]\] as well as in OAB patients \[[@R36]\]. Thus, CLQ treatment suppresses detrusor over-activity and leads to the improvement of the bladder function of PBOO mice. Recently, Long et al. showed that CLQ can prevent the hypertrophy of right ventricular through the inhibition of autophagy pathways \[[@R37]\], raising the possibility that there are the other mechanisms responsible for the effects of CLQ treatment.

In this study, the OAB model was generated with female mice because of the ease of manipulation. It is known that animal models always have several limitations, including the fact the prevalence of bladder obstruction is higher in males than in females. Besides the obstruction of bladder outlet, there are numerous causes of OAB in human. Thus, the effects of CLQ needs to be further investigated with the other OAB models.

There is an unmet need for additional therapeutic options in the treatment of OAB. Here, we provide evidence of the existence of TAS2Rs in both human and mouse urinary DSM and further demonstrate that CLQ can improve OAB symptoms of PBOO mice. Indeed, many known synthetic agents and thousands of natural bitter tastants and their metabolites can activate TAS2Rs and have favorable therapeutic profiles. Therefore, these findings open a new approach to develop drugs for OAB in the future.

MATERIALS AND METHODS {#s4}
=====================

This study was reviewed and approved by the local Institutional Review Board of Peking University First Hospital and the Institute of Biophysics Committee. For experiments involving human subjects, the research was conducted according to the principles expressed in the Declaration of Helsinki. Animal protocols were performed according to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996).

Obtainment of human urinary bladder tissues {#s4_1}
-------------------------------------------

Human urinary bladder tissues were obtained from 26 patients with bladder cancer (18 men and 8 women, mean age: 66 ± 7 yr) who had undergone radical cystectomy in Peking University First Hospital. The patients with urinary retention, obvious lower urinary tract symptoms, or with medical conditions that could affect bladder function were excluded. In addition, the patients whose DSM layers were severely affected by cancer were also excluded. Bladder tissues were removed and confirmed to be cancer-free by an experienced urological pathologist. After the cleaning of fat tissue and peeling of bladder serosa and mucosa, human DSM samples were collected.

Adult C57BL/6J mice (8-week old, 18-22 g) were purchased from Vital River Laboratories (Beijing, China), housed with free access to food and water and maintained on a 12 hour light/dark cycle. Mice were anesthetized by 5% chloral hydrate and the whole bladder was removed, placed into cold Tyrode solution composed of (mM): 137 NaCl, 5.4 KCl, 1.8 CaCl~2~, 1.0 MgCl~2~, 10 glucose, 10 HEPES, (pH 7.4). After the cleaning of the fat tissues, the bladder was cut into two longitudinal pieces by using a fine dissecting scissors along the axis from the neck to the fundus. Then, the urothelium was carefully removed. The DSM tissues were collected for organ baths or RT-qPCR experiments.

RT-qPCR {#s4_2}
-------

RNA and cDNA were prepared as previously reported \[[@R38]\]. In brief, total RNA was prepared from bladder DSM using the Trizol RNA purification system (Invitrogen, Carlsbad, CA, USA). The cDNA was generated from mRNA (2 μg) using the M-MLV reverse transcriptase (Promega Corp., Madison, WI, USA). RT-qPCR was performed on a Corbett Rotor-Gene 6600 QPCR system machine (Corbett Life Science) using TransScript™ Green RT-qPCR SuperMix (TRANSGENE BIOTECH, Beijing, China) according to the manufacturer\'s instructions. GAPDH was used as a reference gene. Detailed information regarding the primer pairs used in this study was shown in Table [1](#T1){ref-type="table"}. All the PCR products were run on the gel or sequenced to test the specificity of each pair of primer. The 2^−ΔCt^ method was used to analyze the relative expression levels of TAS2Rs.

###### Sequence information of RT-qPCR primers

  Gene symbol   Accession number   Forward sequence             Reverse sequence               Size (bp)
  ------------- ------------------ ---------------------------- ------------------------------ -----------
  TAS2R1        NM_019599.2        tgccattgcttatcttccttttt      ggtgtgcctccccagaga             62
  TAS2R3        NM_016943.2        caaaaaccaagatggctaagatga     tgagtggccagcaggataaaa          65
  TAS2R4        NM_016944.1        tttcctgaacttgtgactacgagaa    taaagacaagatgccctcactgata      66
  TAS2R5        NM_018980.2        cagcattcggtatccctttga        tcctgaattgagctgaaatgca         61
  TAS2R7        NM_023919.2        aacgctgctccccttttgt          cgcagggagaggatcaagag           60
  TAS2R8        NM_023918.1        aaaactctatgctaccggcagtaga    agtcatagttttaatggctctcacatg    70
  TAS2R9        NM_023917.2        tgcatgctacagggttcagaga       tgcctttatggccctcatgt           59
  TAS2R10       NM_023921.1        catttccctttggagacacaac       atgagcttctgtgttggagtc          76
  TAS2R13       NM_023920.2        aggagcagaaaaaggagaagg        gtgaagatactcggcaggg            147
  TAS2R14       NM_023922.1        cctcactgctttggcaatctc        acacacaccagcttccgaatatt        65
  TAS2R16       NM_016945.2        cattggttattcctttcatcctgtt    cttggtcagtgatgccatgaga         65
  TAS2R19       NM_176888.1        cgaaccatttcagcatgtgg         ccccaacagtatcaccagaac          134
  TAS2R20       NM_176889.2        agatggagtcttgccctgttgt       ttgtggtgagccaagattgtg          62
  TAS2R30       NM_001097643.1     atttcagcagctggcttgcta        aaattggcaatcctgagcaaa          61
  TAS2R31       NM_176885.2        cagcaccaaggtccacataaaa       gtaaacggcacataacaagaggaa       67
  TAS2R38       NM_176817.4        ctctgtgcccctactgattctgt      cattatcccaacacaaaccatcac       64
  TAS2R39       NM_176881.2        ccctgccagccactcaat           ccgcttccaggctcttctc            64
  TAS2R40       NM_176882.1        tgccggccactcagtacaa          accgcttccaggctcttctc           62
  TAS2R41       NM_176883.2        cggccgacagttcttcca           aaaaccagaaggtggctgagttc        59
  TAS2R42       NM_181429.1        actggtaaactgctctgaagg        atgtgaagcaagtcccactag          139
  TAS2R43       NM_176884.2        gcaccaaggtccacataaaagc       aagtaaatggcacataacaagaggaa     67
  TAS2R45       NM_176886.1        cctttgctgaccaaattgtcact      taataataacacccagagcaaaccaa     68
  TAS2R46       NM_176887.2        gctattgcattcagctatccttca     agcttcttgtttccccaaatca         62
  TAS2R50       NM_176890.2        gttgtcatggttagcaaggc         gagttgagagtttcaggtcttttac      148
  TAS2R60       NM_177437.1        caatgcccactgctgtctttt        tgtgtcttcccagagatgtgatg        63
  hGAPDH        NM_002046.5        gccacatcgctcagacacc          cccaatacgaccaaatccgt           64
  Tas2r102      NM_199153.2        ggaagcttggtgttcttgcttgg      agatcagctcggtccacattgc         127
  Tas2r103      NM_053211.1        attagcactgggtttacactcacc     ccacagggagaagatgagcagaag       75
  Tas2r104      NM_207011.1        agcttcctttccgctagctgtg       tggatcagccaggatgtgttgc         75
  Tas2r105      NM_020501.1        ttccttctcatcggcttagca        gtcaggtgattcacagtcatcc         152
  Tas2r106      NM_207016.1        tgcctctgatgcccacattatag      ggctggtggcaaaccatatacttg       80
  Tas2r107      NM_199154.1        tccctgcggtcactcaatcatc       cagtgccttcaaagaggcttgc         70
  Tas2r108      NM_020502.1        agtgtttctcctgttgaaacggac     tggtgagggctgaaatcagaag         83
  Tas2r109      NM_207017.1        gtcaaattcaggtgttaggaagtcac   cacagggagaagatgagcagga         94
  Tas2r110      NM_199155.2        tggatagtgaataaccatttcagcg    ctccactttaggtaaagaaacaaagagt   110
  Tas2r113      NM_207018.1        tccgcactgctctggcaattag       tgaacagacacccaccaatctagg       73
  Tas2r114      NM_207019.1        tgctgagcacaatggaaggtgtc      tgttccctacaatgcccagcac         72
  Tas2r115      NM_207020.1        ctttggtgtatccttgatagctttcc   gtactgcatcttccttacatgtttcat    73
  Tas2r116      NM_053212.1        cttttgctgtgtcactggtca        tctgatgtgggccttagtgct          119
  Tas2r117      NM_207021.1        cttttcgttgtattttgtgaggttgt   ctgtctcagcttcatgtctcctaca      90
  Tas2r118      NM_207022.1        aagttgcacaacggttgcagtg       tctccaccggtgacagtctttg         68
  Tas2r119      NM_020503.2        ctcaaggaacccaagactcagtg      acaggcttctgagcaggatgtc         82
  Tas2r120      NM_207023.1        atggcaaaggatgtcaagatcag      atgacctgctgggtagaagga          182
  Tas2r121      NM_207024.1        ctggtcttattggagatgattgtgtt   ggagaagattaacaggatgaaggaga     81
  Tas2r122      NM_001039128.1     tcttctctttatggagccaccttag    gtgcttctgtgcttatgtctttgg       75
  Tas2r123      NM_207025.1        cattaaagccttgcaaactgtgttc    ggaaaagtaagtatatggcatacagca    62
  Tas2r124      NM_207026.1        agtctctggcttgctacagctc       agcttcccagaagcatgtggac         127
  Tas2r125      NM_207027.1        atcttctccctgtggagacacctg     tggtgtcttcggagcctttagc         64
  Tas2r126      NM_207028.1        gcagtgtgtgggattggtcaac       tcccggagtactcaaccagatg         62
  Tas2r129      NM_207029.1        ttgcagatgcccacatcagagtc      tggcacagagtaggacataggtg        60
  Tas2r130      NM_199156.1        tccttcctggccctgtttg          tgaatggcttgaaggatagattagag     132
  Tas2r131      NM_207030.1        atcaacatggcttgccacctg        agcacacctctcaatctccactta       105
  Tas2r134      NM_199158.1        gcctgggaagtggtaacctaca       gtgttgcttagtatcagaatggtgga     63
  Tas2r135      NM_199159.1        tcagttctgccagcaacacacc       tgaatcaccacctgccacatcc         64
  Tas2r136      NM_181276.1        tctggaggaaccaatccacctg       tgctctcacctgaaccattgcc         133
  Tas2r137      NM_001025385.1     ctggctcaaatggagagcttcta      ggtactgacacaggataagagcagtg     76
  Tas2r138      NM_001001451.1     tgctattcagctcgcctgcttc       tggcttggtagttgtggctcag         62
  Tas2r139      NM_181275.1        tgacaatgttcgtcgcaacagc       tcatgttcagggtgtgtctcctg        66
  Tas2r140      NM_021562.1        catctgaagaacatgcaacacaatg    gcagggccttaatatgggct           73
  Tas2r143      NM_001001452.1     ttcccaggctgctggttgtatc       agttcccggtggctgaaatgac         69
  Tas2r144      NM_001001453.1     tggtttgctgcttggctcaatg       tcagaaggaacagagggtgagc         73
  mGapdh        NM_008084.2        aaggtcggtgtgaacggatttg       tcctggaagatggtgatgggct         224

Isometric DSM tension recordings {#s4_3}
--------------------------------

Organ bath experiments were performed as previously reported \[[@R39], [@R40]\]. In brief, the mucosa-free DSM strips from human or mouse were dissected into strips 5-8 mm long and 2-3 mm wide. Strips were tied up and mounted in the standard organ bath chambers (BL-420F acquisition system, Chengdu TME Technology Co, Ltd, Sichuan, China) filled with KREBs solution maintained at 37°C and aerated with 95% O~2~ and 5% CO~2~. DSM strips were passively stretched and equilibrated for 1.5 hour. After equilibration, KCl (80 mM) or carbachol (10 μM) were applied to pre-contract the DSM strips. CLQ, denatonium, and quinine were prepared as 1, 000x in MilliQ water just before use. The equal volume of MilliQ water was used as positive controls. When the contraction responses were stable, cumulative CLQ (100 nM to 3 mM) or the positive controls was added to the chambers. To analyze the effects of CLQ, denatonium, and quinine, the stable contractions induced by KCl (80 mM) or carbachol (10 μM) was taken as 100% and the responses to subsequent bitter tastants or control applications were normalized. For EFS experiments, DSM contractions were generated by applying increasing EFS frequencies (0.5, 2, 3.5, 5, 7.5, 10, 12.5, 15, 20, 30, 40, 50 Hz). EFS pulses were generated using the BL-420F acquisition system (Chengdu TME Technology Co, Ltd) and had the following parameters: pulse amplitude was 20 V, pulse width was 0.75 ms, stimulus duration was 3 s, and polarity was reversed for alternating pulses according to a previous study \[[@R25]\]. Five minutes after the addition of 100 μM CLQ, a second EFS stimulation with same frequencies was applied. To analyze the effects of CLQ on the EFS generated contractions, the contraction amplitude at 0.5 Hz of the first EFS stimulation was taken as one and the other contraction amplitudes were normalized to it and shown as fold changes.

Partial bladder outlet obstruction {#s4_4}
----------------------------------

The OAB mouse model was induced with female C57BL/6J mice (8-week old, 18-22g) as previously described \[[@R41]\]. In brief, mice were anesthetized with 5% chloral hydrate, then abdomen was opened by a lower midline incision. The bladder and urethra were carefully separated from the surrounding tissues. After placing a 0.5-mm metal rod alongside the proximal urethra, a 4-0 nylon ligature was tied both the rod and the urethra to make an infravesical obstruction. The rod was subsequently removed, before closing the abdomen. Sham-operated animals served as controls. Two weeks after surgery, the PBOO mice were divided into two subgroups as follows: one group received once 30 mg/kg of CLQ for 6 weeks *via* oral gavage (as PBOO-CLQ mice), and the other group received normal saline (as PBOO-Vehicle mice). The sham-operated mice received normal saline only.

Histological examination {#s4_5}
------------------------

The urinary bladders were fixed with 4% paraformaldehyde, embedded in paraffin and sectioned (5 μm) onto glass slides. HE staining and Masson\'s trichrome staining were carried out by using standard protocols. Images were acquired on a Leica SCN400 Scanner microscope (Leica). To determine the bladder muscle thickness, images of HE staining were analyzed by Image J. Nine non-overlapping fields per mouse bladder were measured and the mean of the bladder muscle thickness was calculated. To measure the ratio of collagen/muscle in the bladder muscle layer, images of masson\'s trichrome staining were analyzed by using Image Pro Plus software. Through color recognition, this system automatically measures the area of each color. Nine fields per mouse bladder were manually chose and analyzed. This analysis was carried out by a single person, who was completely blinded to the experimental data and all other variables.

Cystometry {#s4_6}
----------

As reported previously \[[@R42]\], the mice underwent a surgical procedure for catheter (PE-10) insertion. The mice were anesthetized with 5% chloral hydrate. The abdomen was opened and a PE-10 catheter was inserted into the bladder and fixed with a surgeon\'s knot. After closure the muscle, the catheter was tunneled subcutaneously and an orifice made at the back of the animal. Three days after surgery, conscious mice were placed in cages without any restraints. The PE-10 tube was connected to a pressure transducer (LABORIE, Canada) and an infusion pump (B. Braun Medical, Inc., Germany) through a 3-way tap. Saline solution (37°C) was infused into the bladder at a rate of 1.2 ml/h. Urodynamic values were recorded continuously using data acquisition software (LABORIE, Canada). The following cystometric parameters were recorded and analyzed in this study: maximal micturition pressure at the start of micturition, micturition frequency, and inter-micturition interval.

Statistical analysis {#s4_7}
--------------------

Data were represented as mean ± SEM of n strips in organ bath experiments and N mice in histological-examination/cystometry experiments. Significant differences were determined by Student\'s *t*-test. Only results with values of *p* \< 0.05 were considered significant.
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